As aconsequence we decided to adopt an inhibition strategy and elected to concentrateour efforts on VEGF because there are established inhibitors29, 30, 31 and a range of therapeutic agents commonly used in the clinic to treat the wetform of age-related macular degeneration (AMD)32. This evidence concerns the gene VEGFA and age-related macular degeneration.